The Factors Associated with the Decision of r-tPA Use in Acute Ischemic Stroke Patients Aged 80 Years or Older / 대한뇌졸중학회지
Korean Journal of Stroke
;
: 79-84, 2011.
Article
in Korean
| WPRIM
| ID: wpr-10201
ABSTRACT
BACKGROUND:
Small proportions of all the elderly stroke patients receive recombinant tissue plasminogen activator (r-tPA) therapy, although old age is not a proven contraindication to intravenous thrombolytic therapy for acute ischemic stroke. The purpose of this study was to identify reasons for exclusion from r-tPA therapy and factors associated with the decision of r-tPA use in elderly patients with acute ischemic stroke.METHODS:
From the acute stroke registries of 22 domestic university hospitals taking the r-tPA therapy from January 2007 to May 2010, we extracted data of all acute ischemic stroke patients who were aged 80 or over and arrived within onset 3 hours. For all patients, we assessed the eligibility of r-tPA therapy using National Institute of Neurological Disorders and Stroke (NINDS) r-tPA trial criteria. For eligible patients, we compared all clinical variables between patients who were treated with r-tPA and those who were not, and analyzed potential factors related to the decision of r-tPA use.RESULTS:
A total of 494 patients were included in this study. 255 patients (51.6%) were excluded by NINDS r-tPA trial criteria and the major reasons for exclusion were minor neurological deficit (53.7%) and clinical improvement (17.3%). Among 239 patients who were eligible for r-tPA, 162 (32.8%) patients received r-tPA and 77 (15.6%) did not. Multivariable analysis showed that younger age, shorter time-delay from onset to admission, non-smoker, no history of prior stroke, good pre-stroke functional status and severe initial neurological deficit were independently associated with the decision of r-tPA use in the elderly stroke patients predictors for r-tPA treatment.CONCLUSION:
In very elderly patients, mild neurological deficit on arrival and rapid clinical improvement in neurological symptoms were the main reasons for exclusion from thrombolytic therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombolytic Therapy
/
Registries
/
Tissue Plasminogen Activator
/
Stroke
/
National Institute of Neurological Disorders and Stroke (U.S.)
/
Hospitals, University
Type of study:
Prognostic study
Limits:
Aged
/
Humans
Language:
Korean
Journal:
Korean Journal of Stroke
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS